Citations

Clear

97 citation(s) found for "Ghanem, R".

Metabolic and Bariatric Surgery vs Glucagon-like peptide-1 Receptor Agonist Therapy
Ghusn, Wissam, Abedalqader, Tala, Ghazal, Nour El, Espinosa, Maria Antonia, Villamarin, Jose, Gutierrez, Rene Rivera, Castaneda, Regina , Bechenati, Dima , Fansa, Sima , Hurtado, Maria D., Acosta, Andres, Ghanem, Omar M., Jawhar, Noura , El Ghazal, Nour , Castaneda, Regina , Ghusn, Wissam , Vierkant, Robert A. , Abedalqader, Tala , Villamarin, Jose L. , Gutiérrez, René de Jesús Rivera , Hurtado, M D, Acosta, Andres , Ghanem, Omar M.

Mayo Clinic

Annals of Surgery | April 20, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1097/sla.0000000000007064 | PMID 42002851 Get It

Objective: To compare 1-year changes in estimated 10-year and lifetime atherosclerotic cardiovascular disease (ASCVD) risk following metabolic and bariatric surgery (MBS) versus glucagon-like peptide-1 receptor agonist (GLP-1RA) therapy among adults with obesity. Summary Background Data: Obesity is a major driver of ASCVD through adverse metabolic and inflammatory pathways. Metabolic and bariatric surgery and GLP-1 receptor agonists represent the most effective contemporary treatments for obesity and are increasingly used to mitigate cardiovascular risk. However, their comparative effects on integrated short-term and lifetime ASCVD risk in real-world clinical practice remain incompletely characterized. Methods: We conducted a retrospective cohort study of adults with obesity (body mass index ≥30 kg/m²) who underwent MBS or initiated GLP-1RA therapy between 2020 and 2023 within a large tertiary health care system in the United States. Participants were identified from electronic health records and followed for 12 months. Primary outcomes were 1-year changes in estimated 10-year and lifetime ASCVD risk. Secondary outcomes included percent total body weight loss, blood pressure, and lipid parameters. Multivariable linear regression models were used to adjust for baseline body mass index and baseline ASCVD risk. Results: The final cohort included 812 patients, of whom 579 underwent MBS and 233 initiated GLP-1RA therapy. At baseline, patients receiving GLP-1RAs were older and had higher estimated ASCVD risk. At 1 year, reductions in 10-year ASCVD risk were similar between groups (−0.8% vs. −1.1%; P =.36). In contrast, lifetime ASCVD risk decreased significantly more following MBS than GLP-1RA therapy (−8.6% vs. −1.7%; P <.001). MBS was associated with greater percent total body weight loss (−27.8% vs. −11.1%; P <.001) and more favorable lipid changes, including larger reductions in low-density lipoprotein cholesterol and greater increases in high-density lipoprotein cholesterol. After adjustment, MBS remained independently associated with a greater reduction in lifetime ASCVD risk compared with GLP-1RA therapy (β −6.92; 95% CI −9.22 to −4.62). Conclusions: In this real-world cohort, both MBS and GLP-1RA therapy were associated with improvements in estimated cardiovascular risk, but MBS conferred substantially greater reductions in lifetime ASCVD risk, accompanied by superior weight loss and lipid improvements. These findings highlight the complementary roles of surgical and pharmacologic therapies in obesity management and may inform strategies to optimize long-term cardiovascular risk reduction.
Metabolic and bariatric surgery for patients with obesity type 1 diabetes mellitus: A comprehensive updated systematic review and meta‐analysis
Mitchell, Sebastian , Patwardhan, Ketaki, Geropoulos, Georgios, Lamb, PJ, Ghanem, Omar, Stimson, Roland H. , Lucocq, James E. , Geropoulos, Georgios, Ghanem, Omar M. , Robertson, Andrew G.

Mayo Clinic

Diabetic Medicine | March 29, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1111/dme.70305 | PMID 41904365 Get It

Abstract Aims This systematic review evaluated the impact of metabolic and bariatric surgery (MBS) on weight loss, glycaemic control, insulin requirements and postoperative complications. Methods A PRISMA‐compliant, PROSPERO‐registered systematic review and meta‐analysis (CRD42025123500) was conducted. Medline, PubMed, Embase, Scopus and CENTRAL were searched. Primary outcomes were changes in body weight, BMI, HbA1c and insulin requirements following MBS. Risk of bias was assessed using ROBINS‐I and RoB‐2, and certainty of evidence using GRADE. Results Twenty‐two studies, including 1324 adults with type 1 diabetes mellitus (mean age 42.2 ± 11.6 years; mean follow‐up 31.6 ± 18.2 months), were analysed. Of 753 participants with reported sex, 74.6% were women ( n = 562). A total of 1304 procedures were performed, most commonly Roux‐en‐Y gastric bypass (44.5%; n = 580) and sleeve gastrectomy (39.2%; n = 512), followed by adjustable gastric banding (13.0%; n = 170). Meta‐analysis demonstrated significant reductions in body weight (mean difference 29.55 kg; 95% CI 25.72 to 33.39; I 2 = 20%) and BMI (11.35 kg/m 2 ; 95% CI 10.36 to 12.34; I 2 = 32%). HbA1c decreased by 4 mmol/mol (95% CI 2.05 to 6.78; I 2 = 19%), and insulin requirements declined by 43%–48% (0.20 U/kg; 95% CI 0.13 to 0.26; I 2 = 58%). Postoperative complications included diabetic ketoacidosis (15/182, 8%) and severe hypoglycaemia (21/516, 4%); any complication occurred in 21/495 (4%). Evidence quality was low. Conclusion MBS achieves weight loss and reduces insulin requirements in adults with type 1 diabetes mellitus and obesity, but glycaemic improvements are minimal. Given the observational evidence base and inconsistent safety reporting, true metabolic risk remains uncertain. High‐quality prospective studies with standardised outcome definitions are needed.
Abdominal arterial calcification profile in kidney transplant candidates: a comparison between patients with autosomal dominant polycystic kidney disease and those with other causes of kidney failure
Ghanem, R, Yazbek, Albaraa, Idilbi, Amro , Alhalabi, Alaa , Hanouneh, Tareq, Hassoun, Ali, Nasrini, Tala , Mawaldi, Mohammad, Haddad, Walid, Hallak, Mohammad Hussam, Sella, David M., Alexander, Lauren F. , Li, Zhuo, Chebib, Fouad T, Li, Zhuo , Ghanem, Roaa , Hassoun, Alia A L, Jarmi, Tambi , Alexander, Lauren F , Alhassoun, Alia, Hallak, Mohamed Hussam, Chebib, Fouad T. , Jarmi, Tambi

Mayo Clinic

Journal of Nephrology | March 10, 2026 | Volume: 39 | Issue: 2 | Pages: 399-407

10.1093/joneph/aajaf046 | PMID 41806024 Get It

Abstract Background Abdominal arterial calcification is a well-established predictor of cardiovascular events and mortality in kidney failure. Autosomal dominant polycystic kidney disease (ADPKD), a common genetic cause of kidney failure, presents with a distinct vascular profile. However, the burden of abdominal arterial calcification in ADPKD remains inadequately characterized. Clarifying these differences may improve cardiovascular risk stratification and transplant timing. Methods We conducted a retrospective cohort study of 4088 adult patients listed for kidney transplant at three Mayo Clinic sites (2005–2024). Patients were categorized by kidney failure cause: ADPKD vs. non-ADPKD. Abdominal arterial calcification was quantified on non-contrast computed tomography (CT) scans using a modified Agatston scoring method. Propensity score matching (1:1) adjusted for age, sex, race, lipid levels, left ventricular ejection fraction, dialysis exposure, coronary artery disease, neurovascular disease, and smoking history, was performed. Abdominal arterial calcification scores were compared between matched groups, and subgroup analyses evaluated abdominal arterial calcification severity across dialysis durations in ADPKD patients. Results After matching, 309 patients with ADPKD were compared with 309 non-ADPKD chronic kidney disease (CKD) controls. Abdominal arterial calcification scores were significantly lower in the ADPKD group (median: 425.3; IQR: 0.0–2033.5) than in the non-ADPKD group (median: 1256.8; IQR: 96.5–5033.8). Among ADPKD patients, abdominal arterial calcification scores increased with dialysis duration (P &lt; .001). Conclusion ADPKD patients exhibit lower abdominal arterial calcification scores than their non-ADPKD counterparts after adjusting for clinical variables. Abdominal arterial calcification progression with dialysis highlights the importance of early transplant evaluation. This study introduces a novel adaptation of coronary calcium scoring software for quantifying abdominal calcification, offering a standardized approach to vascular risk assessment in kidney transplant candidates.
The Complexities of Reoperative Metabolic and Bariatric Surgery–A Retrospective Review of Outcomes at a Single Large Institution
Bocchinfuso, Sara , Abedalqader, Tala, Ghazal, Nour El, Laplante, Simon , Mehta, Kabir , Ghanem, Omar M., Ghazal, Nour El , Jawhar, Noura , El Ghazal, Nour , Sample, Jack W. , Abedalqader, Tala , Ghanem, Omar M.

Mayo Clinic

Surgical Laparoscopy, Endoscopy & Percutaneous Techniques | March 9, 2026 | Volume: 36 | Issue: 3 | Pages: No page available

10.1097/sle.0000000000001455 | PMID 41800697 Get It

Background: Reoperative metabolic and bariatric surgery (MBS), consisting of revision and conversion surgery, carries higher morbidity and mortality compared with primary procedures, yet robust long-term data are limited. Methods: A retrospective review was conducted of all patients 18 years of age or older who underwent first-time reoperative MBS between 2000 and 2024 at a single large quaternary referral center. Data were stored securely and analyzed in R (v4.4.2) using standard descriptive statistics and group tests ( t tests/Wilcoxon/Kruskal-Wallis; χ²/Fisher). Sparse late-complication data precluded pairwise tests. Results: Three hundred sixty patients, 86% female, mean age 50 years, underwent reoperative MBS. Conversion to Roux-en-Y gastric bypass (49%) was the most common surgery. The majority were performed for weight recidivism (37%). Length of stay, estimated blood loss, length of surgery, complication rates, readmission rates, and reintervention rates varied by type of reoperative MBS performed and indication. Most early complications were Clavien-Dindo 2, and most late complications were Clavien-Dindo 3b for all approaches. There was one procedure-related death in the study following an open conversion. Conclusion: In this 24-year single-center cohort, weight recidivism was the most frequent indication for reoperation and was associated with improved perioperative outcomes and durable long-term weight loss. As the landscape of bariatric surgery continues to evolve, we recommend early referral to centers with reoperative MBS expertise.
Abdominal Arterial Calcification Score‐Association With Patient Survival Post Kidney Transplant
Idilbi, Amro , Ghanem, R, Hanouneh, Tareq, Hassoun, Ali, Nasrini, Tala , Haddad, Walid, Hallak, Mohamed Hussam, Sella, David M., Craver, Emily C. , Alasfar, Sami , Ghanem, Roaa, Alhassoun, Alia, Stegall, Mark D , Schinstock, Carrie , Jarmi, Tambi , Alhassoun, Alia, Alexander, Lauren F. , Stegall, Mark D. , Schinstock, Carrie A. , Jarmi, Tambi

Mayo Clinic

Clinical Transplantation | November 12, 2025 | Volume: 39 | Issue: 11 | Pages: No page available

10.1111/ctr.70387 | PMID 42578517 Get It

ABSTRACT Background Abdominal arterial calcification (AAC) is a common comorbidity in patients with end‐stage kidney disease (ESKD) and a predictor of cardiovascular events post‐kidney transplant. However, prior studies lacked a standardized approach to evaluate AAC and its impact on post‐transplant outcomes. This study aimed to correlate AAC score values with post‐kidney transplant outcomes using a modified scoring system traditionally applied to coronary artery calcification. Methods This retrospective study included 14 339 adult patients listed for kidney transplant between 2002 and 2023 at three transplant centers. Among them, 3683 patients met the criteria of undergoing a kidney transplant and an abdominal computed tomography (CT) scan pre‐transplant. We modified the coronary calcium score software by adjusting intake data points to quantify calcification in the abdominal aorta, common iliac, external iliac, and internal iliac arteries. Outcomes focused on post‐transplant mortality. Results In 3683 kidney transplant recipients, higher AAC scores were significantly associated with increased mortality. Each 1000‐unit increase in AAC score elevated hazard ratios (HRs) across arterial regions, including 1.116 for the aorta and 1.389 for the internal iliac (all p < 0.001). Adjusted analyses confirmed AAC as an independent risk factor for mortality. Kaplan–Meier curves demonstrated lower survival with increasing AAC quartiles. Conclusions AAC, measured by a standardized score, is a significant mortality risk factor in kidney transplant recipients. Integrating AAC scores into pre‐transplant evaluations could enhance risk stratification and improve outcomes. Prospective studies are needed to validate these findings and explore interventions to reduce AAC and improve survival.
Sodium-Glucose Cotransporter 2 Inhibitors in Autosomal Dominant Polycystic Kidney Disease
Antoun, Mikhail D., Borghol, Abdul Hamid , Souvalian, Levon , Hadla, Mohamad , Abboud, Georges , Ghanem, Ahmad , Debeh, Fadi George Munairdjy , Mardirossian, Jean Marc , Salih, Mahdi , Vallon, Volker , Bou Antoun, Marie Therese , Munairdjy Debeh, Fadi George , Garimella, Pranav S , Vallon, Volker , Chebib, Fouad T , Hadla, Mohamad , Mardirossian, Jean Marc , Garimella, Pranav S. , Chebib, Fouad T.

Mayo Clinic

Journal of the American Society of Nephrology | November 10, 2025 | Volume: 37 | Issue: 4 | Pages: 861-880

10.1681/asn.0000000943 | PMID 41212622 Get It

Autosomal dominant polycystic kidney disease (ADPKD) is the most common inherited kidney disorder and a leading cause of kidney failure worldwide. Disease progression is driven by cyst expansion, tubular injury, and maladaptive metabolic and hemodynamic changes. Tolvaptan remains the only US Food and Drug Administration–approved disease-modifying therapy, however its tolerability and safety profile highlight the need for additional strategies. Sodium-glucose cotransporter 2 inhibitors (SGLT2is), initially developed for glycemic control, have demonstrated robust kidney-protective and cardioprotective effects across diverse patient populations, including those without diabetes. By lowering intraglomerular pressure, metabolic reprogramming, and attenuating hypoxic microenvironment and inflammation, SGLT2is target mechanisms that are relevant to ADPKD. However, concerns that SGLT2i may provoke osmotic diuresis and activate vasopressin led to systematic exclusion of patients with ADPKD from pivotal outcome trials. The 2025 Kidney Disease Improving Global Outcomes ADPKD guidelines explicitly advise against the use of SGLT2i for slowing kidney function decline in ADPKD. In this review, we examine mechanistic intersections between SGLT2i and ADPKD pathophysiology, summarize available preclinical and early clinical data, and discuss ongoing large trials designed to address safety and efficacy of SGLT2i in patients with ADPKD. We also highlight the importance of genetic heterogeneity, as most ongoing trials are enriched for rapid progressors carrying PKD1 or PKD2 pathogenic variants, while other genotypes such as DNAJB11 , ALG8 , and ALG9 , often associated with greater interstitial fibrosis, are underrepresented. Substratification of patients by genotype, risk of progression, and comorbidities will be essential to guide precision application of SGLT2i. Whether SGLT2i can ultimately be positioned as an adjunctive or standalone therapy for ADPKD remains unresolved.
Genotype-Phenotype Characterization of PKD1 Missense Variants in ADPKD: Insights from Structural Imaging Biomarkers
Antoun, Mikhail D., Borghol, Abdul Hamid , Debeh, Fadi George Munairdjy , Gregory, Adriana , Yang, Hana , Schauer, R., Kline, Timothy L. , Ghanem, Ahmad , Schauer, Rachel S., Hanna, Christian , Harris, Peter C. , Chebib, Fouad T.

Mayo Clinic

Journal of the American Society of Nephrology | October 23, 2025 | Volume: 36 | Issue: 10S | Pages: No page available

10.1681/asn.2025m0qx0bbm Get It

Procedure-Specific Early Complications Following Bariatric Surgery: A High-Volume Single-Institution Analysis
Ghusn, Wissam , Ghazal, Nour El , Kellogg, Todd A., Ghanem, Omar M., El Ghazal, Nour , Mosleh, Kamal Abi , Jawhar, Noura , Salameh, Yara , Ghanem, Omar M.

Mayo Clinic

Surgical Laparoscopy, Endoscopy & Percutaneous Techniques | September 22, 2025 | Volume: 35 | Issue: 6 | Pages: No page available

10.1097/sle.0000000000001406 | PMID 40977592 Get It

Background: Metabolic and bariatric surgery (MBS) is an established treatment for severe obesity and its related comorbidities. While long-term outcomes are often emphasized, early postoperative complications remain a critical metric of safety and resource utilization. Large database studies have reported national trends in MBS outcomes but are limited by lack of granularity, inconsistent definitions, and inclusion of heterogeneous surgical experience. This study aimed to provide a detailed analysis of 30-day postoperative complications following sleeve gastrectomy (SG), Roux-en-Y gastric bypass (RYGB), and duodenal switch (DS) over a 17-year period at a single high-volume quaternary academic center. Materials and Methods: A retrospective cohort study of adult patients who underwent primary laparoscopic SG, RYGB, or DS between 2008 and 2024. All procedures were performed by fellowship-trained, minimally invasive bariatric surgeons. Complications occurring within 30 days postoperatively were identified through comprehensive chart review and classified using the Clavien-Dindo grading system. Primary outcomes included incidence, severity, and type of complications, as well as rates of readmission, reoperation, and reintervention. Multivariable logistic regression was used to identify predictors of overall and major complications. Results: Of 2190 patients included, 413 (18.9%) experienced at least 1 early complication, totaling 467 discrete events. DS had the highest complication rate (29.3%), followed by RYGB (18.4%) and SG (17.5%). RYGB was associated with a high burden of major complications, including anastomotic strictures, GI bleeding, and reoperations for obstruction or leak. The 30-day rates of readmission (2.0%) and reoperation (1.3%) were low across all groups. Independent predictors of major complications included venous stasis (aOR=3.22), renal insufficiency (aOR=2.65), and type 2 diabetes (aOR=1.96); both RYGB (aOR=2.25) and DS (aOR=2.77) carried higher risk than SG. Conclusion: This study provides a granular, procedure-specific profile of early complications after SG, RYGB, and DS. While all 3 procedures demonstrated acceptable safety profiles, DS had the highest overall complication rate, and RYGB carried the greatest burden of major complications. These findings underscore the variability in early postoperative outcomes by procedure type and reflect the value of institutional experience in characterizing complication profiles.
Predictors of Intracranial Aneurysm Residual Filling After Treatment With Flow Diversion at Early Follow-up: A Multicenter Experience of 2277 Patients
Burks, Joshua D. , Abdelsalam, Ahmed , Silva, Michael A. , Jabbour, Pascal, Kasab, Sami Al , Kan, Peter , Chalouhi, Nohra , Eatz, Tiffany , Wolfe, Stacey Q , Spiotta, Alejandro M , Yavagal, Dileep R. , Peterson, Eric C. , Wu, Eva M. , Lanzino, Giuseppe, Brinjikji, Waleed , El‐Ghanem, Mohammad , Starke, Robert M. , Wolfe, Stacey Quintero , Luther, Evan , Christopher, Kara M , Jabbour, Pascal, Levitt, Michael R. , Sanikommu, Sai , Abla, Adib A. , Arthur, Adam Stephen , Osbun, Joshua W , Park, Min S. , Sweid, Ahmad , Fargen, Kyle M , Peterson, Eric C., Schirmer, Clemens M. , Almallouhi, Eyad , Lanzino, Giuseppe

Mayo Clinic

Neurosurgery | September 19, 2025 | Volume: 98 | Issue: 1 | Pages: 239-245

10.1227/neu.0000000000003747 | PMID 40970720 Get It

BACKGROUND AND OBJECTIVES: Flow-diverting stents (FDSs) have improved treatment options for intracranial aneurysms. Although FDS have proven successful in treating aneurysms that would previously have required complex microsurgical or endovascular repairs, treatment failures remain a concern. In this multicenter study, we aim to analyze the predictors of residual aneurysmal filling at early angiographic follow-up. METHODS: A retrospective analysis of a prospectively maintained neuroendovascular database at 14 high-volume US centers was conducted for all patients who underwent FDS placement for intracranial aneurysms between 2011 and 2019. Aneurysms were graded on the O'Kelly-Marotta scale (OKM). RESULTS: A total of 2277 patients underwent FDS embolization for intracranial aneurysms during the study period. The patient's mean age was 55 (SD ± 13.5) years, and 82% were female. The median maximal aneurysm diameter was 6.7 mm (IQR 4.10-11 mm). Complete aneurysm obliteration (OKM grade 4) occurred in 1109 patients (68%), and 146 (9%) were OKM grade 3, 188 (12%) were OKM grade 2, and 174 (11%) were OKM grade 1. In the adjusted multivariate analysis, individuals in the 65-74 years and 75+ years age groups had significantly increased risk of residual aneurysm filling at 6-month follow-up compared with the 18-44 years age group (odds ratio [OR] 1.92 (95% CI: 1.33-2.78) and 2.92 (95% CI: 1.79-4.77), respectively). Aneurysms arising from the superior cerebellar artery, the basilar artery, and the carotid terminus were more likely to have a residual filling (OR 12.6, 95% CI: 1.39–14.7; OR 4.27, 95% CI: 1.39–14.7; OR 3.16, 95% CI: 1.24–8.06, respectively). CONCLUSION: As the utilization of FDS for intracranial aneurysms becomes more widespread, the efficacy of aneurysm obliteration needs to be assessed. Our results indicate that several patient-dependent factors, such as age, aneurysm location, and size, predict the likelihood of residual aneurysm filling 6 months post-treatment.